A股異動丨部分核電概念股繼續活躍,利柏特4連板創歷史新高
核電概念股近日持續走強,利柏特(605167.SH)截至今日走出4連板,最新報價12.63元,股價創歷史新高。消息面上,2023年12月29日,由25家央企、科研院所、高校等組成的可控核聚變創新聯合體正式宣佈成立;同一天,經國務院常務會議審議,決定核准廣東太平嶺、浙江金七門核電項目。不過值得注意的是,利柏特昨晚公吿,公司在手訂單中不涉及“可控核聚變”業務。公司尚未確認拓烯科技TAMT®拓美特®系列SOOC產品的銷售對象,該項業務尚未給公司帶來業務收入,預計未來該項業務在公司業務中佔比份額較小,不會對公司經營業績構成重大影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.